GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET

Company Participants

Christian Dinneen-Long - Company Counsel

Harout Semerjian - Chief Executive Officer

Brian Hahn - Chief Financial Officer

Bruce Johnson - Chief Commercial Officer

Conference Call Participants

Boris Peaker - Cowen and Company

Roger Song - Jefferies

Steve Bersey - H.C. Wainwright

Operator

Good morning, and thank you for joining the GlycoMimetics Q2 2022 earnings call. At this time all participants are in listen only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Christian Dinneen-Long company counsel at GlycoMimetics. Please go ahead.

Christian Dinneen-Long

Good morning. Today we will review our business updates and financial results for the quarter ended June 30 2022. The press release we issued this morning is available on the company's website@glycomimetics.com under the Investors tab.

This call is being recorded. A dial in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investor Relations section of the company's website.

Joining me on the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; and Bruce Johnson, Chief Commercial Officer. We will start today's call with comments from Harout, who will provide a broad overview of the business and the progress of our pipeline programs, followed by commentary from Bruce on the potential market opportunity for uproleselan. Brian will then provide detail on the company's financial position, and we'll open the call for Q&A.

I would like to remind you that today's call will include forward-looking statements based on current expectations. Forward looking statements on this call may include, but are not limited to, statements about the company's product candidates, uproleselan, GMI 1687, and our other pipeline programs, along with statements about expectations regarding our operations, cash position, and data from preclinical studies or clinical trials, as well as planned or potential future development, regulatory interactions or submissions, and potential pre-commercialization activities or strategic collaborations. Such statements represent management's judgment and intention as of today, and involve assumptions, risks, and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to GlycoMimetics' filings with the SEC, which are available from the SEC on the GlycoMimetics website.